Lack of evidence of blood pressure-independent protection by renin- angiotensin system blockade after renal ablation

Kidney International

Volumn 57, Issue 4, 2000, Pages 1651-1661

  Bidani, Anil K ^a,b   Griffin, Karen A ^a,b   Bakris, George ^a,b   Picken, Maria M ^a,b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; AT1 receptor antagonist; Glomerulosclerosis; Hypertension; Progressive renal disease

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE MEASUREMENT; CONFERENCE PAPER; DRUG MECHANISM; GLOMERULOSCLEROSIS; HYPERTENSION; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TELEMETRY;

EID: 0034081531     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00009.x     Document Type: Conference Paper

References (59)

1. 1. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA, BRENNER BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85-F93, 1981
2. 2. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
3. 3. FOGO A, ICHIKAWA I: Evidence of central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 9:329-342, 1990
4. 4. BIDANI AK, MITCHELL KD, SCHWARTZ MM, NAVAR LG, LEWIS EJ: Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 38:28-38, 1990
5. 5. NEURINGER JR, BRENNER BM: Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Disease 22:98-104, 1993
6. 6. REMUZZI G, RUGGENENTI P, BENIGNI A: Understanding the nature of renal disease progression. Kidney Int 51:2-15, 1997
7. 7. OLSON JL, HEPTINSTALL RH: Non-immunologic mechanisms of glomerular injury. Lab Invest 59:564-578, 1988
8. 8. STRIKER GE, HE CJ, LIU ZH, YANG DCW, ZALUPS RK, ESPOSITO C, STRIKER LJ: Biology of disease. Pathogenesis of nonimmune glomerulosclerosis: Studies in animals and potential applications to humans. Lab Invest 73:596-605, 1995
9. 9. ANDERSON S, RENNKE HG, BRENNER BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993-2000, 1986
10. 10. ANDERSON S, RENNKE HG, GARCIA DL, BRENNER BM: Short-and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989
11. 11. KAKINUMA Y, KAWAMURA T, BILLS T, YOSHIOKA T, ICHIKAWA I, FOGO A: Blood pressure-independent effect of angiotensin inhibition on glomerular and non-glomerular vascular lesions of chronic renal failure. Kidney Int 42:46-55, 1992
12. 12. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
13. 13. LEWIS EJ, HUNSICKER LG, BAIN RP, RHODE RD: The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
14. 14. KASISKE BL, KALIL RS, MA JZ, LIAO M, KEANE WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
15. 15. MASCHIO G, ALBERTI D, JANIN G, LOCATELLI F, MANN JF, MOTOLESE M, PONTICELLI C, RITZ E, ZUCCHELLI P, THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITION IN PROGRESSIVE RENAL INSUFFICIENCY STUDY GROUP: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
16. 16. HALL JE, BRANDS MW, HENECAR JR: Angiotensin II and long-term arterial pressure regulation: The overriding dominance of the kidney. J Am Soc Nephrol 10(Suppl):S258-S265, 1999
17. 17. TIMMERMANS PB, WONG PC, CHIU AT, HERBLIN WF, BENFIELD P, CARINI DJ, LEE RJ, WEXLER RR, SAYE JM, SMITH RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251, 1993
18. 18. MATSUSAKA T, HYMES J, ICHIKAWA I: Angiotensin in progressive renal disease: Theory and practice. J Am Soc Nephrol 7:2025-2043, 1996
19. 19. YOSHIDA Y, KAWAMAURA T, IKOMA M, FOGO A, ICHIKAWA I: Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36:626-635, 1989
20. 20. KAGAMI S, BORDER WA, MILLER DE, NOBLE NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
21. 21. TANAKA R, SUGIHARA K, TATEMATSU A, FOGO A: Internephron heterogeneity of growth factors and sclerosis: Modulation of platelet-derived growth factor by angiotensin II. Kidney Int 47:131-139, 1995
22. 22. KETTELER M, NOBLE NA, BORDER WA: Transforming growth factor-β and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57:279-295, 1995
23. 23. WOLF G, NEILSON EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540, 1993
24. 24. PARATI G, OMBON S, DIRIENZO M, FRATTOLA A, ALBINI F, MANCIA G: Twenty-four hour blood pressure variability: Clinical implications. Kidney Int 41(Suppl 37):S24-S28, 1992
25. 25. HOLSTEIN-RATHLOU NH, MARSH DJ: Renal blood flow regulation and arterial pressure fluctuations: A case study in nonlinear dynamics. Physiol Rev 74:637-681, 1994
26. 26. BAZIL MK, KRULAN C, WEBB RL: Telemetric monitoring of cardiovascular parameters in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 22:897-905, 1993
27. 27. BIDANI AK, GRIFFIN KA, PICKEN M, LANSKY DM: Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 265:F391-F398, 1993
28. 28. GRIFFIN KA, PICKEN M, BIDANI AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010-1018, 1994
29. 29. GRIFFIN KA, PICKEN M, BIDANI AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4:2023-2031, 1994
30. 30. GRIFFIN KA, PICKEN MM, BIDANI AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 96:793-800, 1995
31. 31. GRIFFIN KA, PICKEN MM, BAKRIS GL, BIDANI AK: Class differences in the effects of calcium blockers in the rat remnant kidney model. Kidney Int 55:1849-1860, 1999
32. 32. RAIJ L, AZAR S, KEANE W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137-143, 1984
33. 33. WEIBEL ER: Serological Methods: Practical Methods for Biological Morphometry. London, Academia, 1979, pp 51-57
34. 34. FRY JC: Biological data analysis: A practical approach, in The Practical Approach Series, edited by RICKWOOD D, HAMES BD, New York, Oxford, OIRL Press at Oxford University Press Inc., 1993
35. 35. PURKERSON ML, TOLLEFSEN DM, KLAHR S: N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J Clin Invest 81:69-74, 1988
36. 36. BIDANI AK, SCHWARTZ MM, LEWIS EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 252:F1003-F1010, 1987
37. 37. PELAYO JC, WESTCOTT JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 88:101-105, 1991
38. 38. NAVAR LG: Renal autoregulation: Perspectives from whole kidney and single nephron studies. Am J Physiol 234:F357-F370, 1978
39. 39. HAYASHI K, EPSTEIN M, LOUTZENHISER R: Pressure-induced vasoconstriction of renal microvessels in normotensive rats. Circ Res 65:1475-1484, 1989
40. 40. HAYASHI K, EPSTEIN M, SARUTA T: Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. J Hypertens 14:1387-1401, 1996
41. 41. LOUTZENHISER R, EPSTEIN M: Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249:F619-F629, 1985
42. 42. CARMINES PK, MITCHELL KD, NAVAR LG: Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int 41(Suppl 36):S43-S48, 1992
43. 43. ROBERTSON CR, DEEN WM, TROY JL, BRENNER BM: Dynamics of glomerular ultrafiltration in the rat. III. Hemodynamics and autoregulation. Am J Physiol 223:1191-1200, 1972
44. 44. PETTINGER WA: Anesthetics and renin-angiotensin-aldosterone axis. Anesthesiology 48:393-396, 1978
45. 45. KEETON TK, CAMPBELL WB: The pharmacologic alteration of renin release. Pharmacol Rev 31:81-226, 1981
46. 46. GRIFFIN KA, BIDANI AK, PICKEN M, OUYANG J, ELLIS VR, CHURCHILL PC: Prostaglandins do not mediate the impaired autoregulation or increased renin secretion in remnant rat kidneys. Am J Physiol 263:F1057-F1062, 1992
47. 47. GRIFFIN KA, PICKEN MM, CHURCHILL M, CHURCHILL P, BIDANI AK: Functional and structural correlates of glomerulesclerosis after renal mass reduction in the rat. J Am Soc Nephrol (in press)
48. 48. LAFFERTY HM, BRENNER BM: Are glomerular hypertension and "hypertrophy" independent risk factors for progression of renal disease? Semin Nephrology 10:294-304, 1990
49. 49. DWORKIN LD, BENSTEIN JA, PARKER M, TOBERI E, FEINER HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808-814, 1993
50. 50. RISER BL, CORTES P, ZHAO X, BERNSTEIN J, DUMLER F, NARINS RG: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90:1932-1943, 1992
51. 51. HARRIS RC, AKAI Y, YASUDA T, HOMMA T: The role of physical forces in alterations of mesangial cell function. Kidney Int 45(Suppl 45):S17-S21, 1994
52. 52. KUDOH S, KOMURO I, KIROI Y, ZOU Y, HARADA K, SUGAYA T, TAKEKOSHI N, MURAHAMI K, KADOWAKI T, YAZAKI Y: Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type Ia receptor knockout mice. J Biol Chem 273: 24037-24043, 1998
53. 53. HARADA K, KOMURO I, SHIOJIMA I, HAYASHI D, KUDOH S, MIZUNO T, KIJIMA K, MATSUBARA H, SUGAYA T, MURAKAMI K, YAZAKI Y: Pressure overload induces cardiac hypertrophy in angiotensin II type Ia receptor knockout in mice. Circulation 97:1952-1959, 1998
54. 54. OTS M, MACKENZIE HS, TROY JL, RENNKE HG, BRENNER BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224-230, 1998
55. 55. DZAU VJ, SASAMURA H, HEIN L: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications. J Hypertens 11:S13-S18, 1993
56. 56. KON V, FOGO A, ICHIKAWA I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I-converting enzyme inhibition. Kidney Int 44:545-550, 1993
57. 57. TANAKA R, KON V, YOSHIOKA T, ICHIKAWA I, FOGO A: Angiotensin-converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 45:537-543, 1994
58. 1 receptor: Gain-of-function study using gene transfer. J Clin Invest 92:10663-10667, 1995
59. 59. ISHIDOYA S, MORRISSEY J, MCCRACKEN R, REYES A, KLAHR S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285-1294, 1995